[1] |
Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine[J]. World J Gastroenterol, 2014, 20(15): 4115-4127.
|
[2] |
Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 381-400.
|
[3] |
Bruix J, Han KH, Gores G, et al. Liver cancer: approaching a personalized care[J]. J Hepatol, 2015, 62(1 Suppl):S144-156.
|
[4] |
Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF)[J]. Cytokine Growth Factor Rev, 2015, 26(5):533-544.
|
[5] |
Gearing DP, Comeau MR, Friend DJ, et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor[J]. Science, 1992, 255(5050):1434-1437.
|
[6] |
Margioula-Siarkou C, Prapas Y, Petousis S, et al. LIF endometrial expression is impaired in women with unexplained infertility while LIF-R expression in all infertility sub-groups[J]. Cytokine, 2017(96):166-172.
|
[7] |
Yu H, Yue X, Zhao Y, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers[J]. Nat Commun, 2014(5):5218.
|
[8] |
Liu SC, Tsang NM, Chiang WC, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance[J]. J Clin Invest, 2013, 123(12):5269-5283.
|
[9] |
Johnson RW, Finger EC, Olcina MM, et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow[J]. Nat Cell Biol, 2016, 18(10):1078-1089.
|
[10] |
Starenki D, Singh NK, Jensen DR, et al. Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice[J]. Cancer Lett, 2013, 339(1):144-151.
|
[11] |
Takahashi Y, Takahashi M, Carpino N, et al. Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway[J]. Mol Endocrinol, 2008, 22(7):1673-1681.
|
[12] |
Huang D, Wang L, Duan J, et al. LIF-activated Jak signaling determines Esrrb expression during late-stage reprogramming[J]. Biol Open, 2018, 7(1): pii: bio029264.
|
[13] |
Albrengues J, Bourget I, Pons C, et al. LIF mediates proinvasive activation of stromal fibroblasts in cancer[J]. Cell Rep, 2014, 7(5):1664-1678.
|
[14] |
Pastuschek J, Poetzsch J, Morales-Prieto DM, et al. Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434[J]. J Reprod Immunol, 2015(108):48-55.
|
[15] |
Zeng H, Qu J, Jin N, et al. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer[J]. Cancer Cell, 2016, 30(3):459-473.
|
[16] |
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4):203-217.
|
[17] |
Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives[J]. Gut, 2014, 63(5):844-855.
|
[18] |
Shi W, Yan D, Zhao C, et al. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista[J]. Biochem Biophys Res Commun, 2017, 491(1):159-165.
|
[19] |
Lei J, Yan L. Outcome comparisons among the Hangzhou, Chengdu, and UCSF criteria for hepatocellular carcinoma liver transplantation after successful downstaging therapies[J]. J Gastrointest Surg, 2013, 17(6):1116-1122.
|
[20] |
Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6):1035-1041.
|